Objectives For revealing the peculiarities of the drug–drug interaction of rivaroxaban
(substrate CYP3A4 and P-gp) and calcium channel blockers (CCBs)(verapamil–inhibitor …

Introduction: More than half of patients with nonvalvular atrial fibrillation (NVAF) are≥ 80
years of age; yet such patients are often underrepresented in studies of oral anticoagulation …

Background: The J-ROCKET AF study found that rivaroxaban was non-inferior to warfarin
with respect to the principal safety outcome in patients with atrial fibrillation (AF). The aim of …

Objective Atrial fibrillation (AF) is the most common abnormal heart rhythm in elderly
patients. Rivaroxaban has been widely used for stroke prevention. The anticoagulant …

The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage
regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A …

Direct oral anticoagulants (DOACs), such as rivaroxaban, reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). However, it is still …

Introduction Infection may induce thrombotic and hemorrhagic events; however, it is
currently unclear whether the inflammatory response affects the coagulation function and the …

Background—Nonvalvular atrial fibrillation is common in elderly patients, who face an
elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor …

Study Objective Patients with nonvalvular atrial fibrillation (NVAF) often have multiple
comorbidities requiring concomitant medications in addition to their oral anticoagulant …

Background: It is important to understand the risk of thromboembolism and bleeding in
patients with nonvalvular atrial fibrillation (NVAF) receiving direct oral anticoagulants; …